Frank Follmann

Frank Follmann

Kontakt

Frank Follmann, Afdelingschef, Afdeling for Infektionsimmunologi / Infektionsimmunologi
T. 32688296 @. frf@ssi.dk

Forskningsområder

Min forskning er centreret omkring samspillet mellem immunsystemet og patogenet, specielt med henblik på at udvikle nye vacciner og diagnostik.
Herunder arbejdes med:

  • Infektionsimmunologiske studier af naturlig erhvervet immunitet
  • Identification af B and T celle antigener
  • Vaccine design vha. genteknologi til at sammensætte komponenter fra bakterier eller virus
  • Forskning i nye vaccinehjælpestoffer (adjuvanser) og alternative vaccinationsformer over slimhinden 

Konkret er hovedmålet med min forskning at udvikle en klamydiavaccine. SSI har igennem 15 år arbejdet med vaccinen og har senest gennemført en klinisk fase I afprøvning i mennesker med lovende resultater.

Ansvarsområder

  • Afdelingschef for Afdeling for Infektionsimmunologi
  • Videnskabelig projektleder for H2020 projekt TracVac (https://www.trachoma-vaccine.org/)

Udvalgte publikationer

  • Abraham S, Juel HB, Bang P, Cheeseman HM, Dohn RB, Cole T, Kristiansen MP, Korsholm KS, Lewis D, Olsen AW, McFarlane LR, Day S, Knudsen S, Moen K, Ruhwald M, Kromann I, Andersen P, Shattock RJ, Follmann F. 2019. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis.

  • Erneholm K, Lorenzen E, Boje S, Olsen AW, Jungersen G, Jensen HE, Cassidy JP, Andersen P, Agerholm JS, Follmann F. 2019. Genital Infiltrations of CD4(+) and CD8(+) T Lymphocytes, IgA(+) and IgG(+) Plasma Cells and Intra-Mucosal Lymphoid Follicles Associate With Protection Against Genital Chlamydia trachomatis Infection in Minipigs Intramuscularly Immunized With UV-Inactivated Bacteria Adjuvanted With CAF01. Front Microbiol 10:197
  • Blakney AK, McKay PF, Christensen D, Yus BI, Aldon Y, Follmann F, Shattock RJ. 2019. Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. J Control Release 304:65-74
  • Rose F, Karlsen K, Jensen PR, Jakobsen RU, Wood GK, Rand KD, Godiksen H, Andersen P, Follmann F, Foged C. 2018. Unusual Self-Assembly of the Recombinant Chlamydia trachomatis Major Outer Membrane Protein (MOMP)-based Fusion Antigen CTH522 into Protein Nanoparticles. J Pharm Sci doi:10.1016/j.xphs.2018.02.005
  • Olsen AW, Lorenzen EK, Rosenkrands I, Follmann F, Andersen P. 2017. Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis. Front Immunol 8:1652
  • Wern JE, Sorensen MR, Olsen AW, Andersen P, Follmann F. 2017. Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract. Front Immunol 8:569.